| Literature DB >> 28720711 |
Jordan K Boutilier1,2, Rhonda L Taylor3,2, Tracy Mann4, Elyshia McNamara1,2, Gary J Hoffman4, Jacob Kenny4, Rodney J Dilley5, Peter Henry4, Grant Morahan1,2, Nigel G Laing1,2, Kristen J Nowak1,4.
Abstract
The pulmonary myocardium is a muscular coat surrounding the pulmonary and caval veins. Although its definitive physiological function is unknown, it may have a pathological role as the source of ectopic beats initiating atrial fibrillation. How the pulmonary myocardium gains pacemaker function is not clearly defined, although recent evidence indicates that changed transcriptional gene expression networks are at fault. The gene expression profile of this distinct cell type in situ was examined to investigate underlying molecular events that might contribute to atrial fibrillation. Via systems genetics, a whole-lung transcriptome data set from the BXD recombinant inbred mouse resource was analyzed, uncovering a pulmonary cardiomyocyte gene network of 24 transcripts, coordinately regulated by chromosome 1 and 2 loci. Promoter enrichment analysis and interrogation of publicly available ChIP-seq data suggested that transcription of this gene network may be regulated by the concerted activity of NKX2-5, serum response factor, myocyte enhancer factor 2, and also, at a post-transcriptional level, by RNA binding protein motif 20. Gene ontology terms indicate that this gene network overlaps with molecular markers of the stressed heart. Therefore, we propose that perturbed regulation of this gene network might lead to altered calcium handling, myocyte growth, and contractile force contributing to the aberrant electrophysiological properties observed in atrial fibrillation. We reveal novel molecular interactions and pathways representing possible therapeutic targets for atrial fibrillation. In addition, we highlight the utility of recombinant inbred mouse resources in detecting and characterizing gene expression networks of relatively small populations of cells that have a pathological significance.Entities:
Keywords: atrial fibrillation; eQTL; gene network; pulmonary myocardium
Mesh:
Substances:
Year: 2017 PMID: 28720711 PMCID: PMC5592927 DOI: 10.1534/g3.117.044651
Source DB: PubMed Journal: G3 (Bethesda) ISSN: 2160-1836 Impact factor: 3.154
Figure 1Identification of a pulmonary myocardium gene network. The top 100 transcripts that correlated with Tnni3 in the BXD whole-lung transcriptome data set were used to generate a network graph. This resulted in a network of 24 transcripts with a Pearson correlation >0.8. (A) These 24 transcripts were subsequently regraphed to interrogate relationships at Pearson correlation values between 0.7 and 1.0 (red lines) and between 0.5 and 0.7 (orange lines). (B) The functional relationships of the 21 proteins translated from these 24 transcripts were also identified. All proteins except DOC2G and MYBPHL had known roles in cardiac function including structural sarcomeric proteins, regulation of sarcomere assembly, ion transport, transcriptional and post-transcriptional regulation, and hormone signaling.
Genes coexpressed with Tnni3 in the BXD whole-lung transcriptome have known roles in the function and regulation of the heart
| Functional Category | Gene | Name | Function |
|---|---|---|---|
| Sarcomeric structural protein | Cardiac troponin I | The troponin complex couples calcium availability with muscle contraction ( | |
| Cardiac troponin T2 | |||
| Cardiac myosin heavy chain 6 (α-MHC) | Two myosin heavy chains, two essential myosin light chains and two regulatory myosin light chains interact to form the thick filament of the sarcomere ( | ||
| Cardiac myosin heavy chain 7 (β-MHC) | |||
| Atrial essential myosin light chain (ALC1) | |||
| Atrial regulatory myosin light chain (MYLC2a) | |||
| Cardiac myosin binding protein C | Modulates the interaction between actin and myosin to regulate power output ( | ||
| Regulation of sarcomere assembly | Myosin light chain kinase 3 | Phosphorylates MYLC2a to facilitate actin–myosin interaction and muscle contraction ( | |
| Ion transport | Potassium inwardly rectifying channel, subfamily J, member 3 | Subunit of the muscarinic potassium channel (KCHa), important in regulation of heart rate ( | |
| Cardiac ryanodine receptor 2 | Mediator of SR calcium storage and release ( | ||
| Cardiac muscle/slow twitch Ca++ transporting ATPase (SERCA2a) | Transports calcium from the cytosol to the SR lumen during muscle relaxation ( | ||
| Phospholamban | Negative regulator of SERCA2a ( | ||
| Sarcolipin | |||
| Triadin | Forms a complex with Ryr2 to coordinate release of calcium from the SR ( | ||
| Fibroblast growth factor 12 | Modulation of sodium and calcium channel function ( | ||
| Transcriptional and post-transcriptional regulation | T-box 20 | Activates chamber myocardial gene expression in the early heart tube ( | |
| RNA binding motif protein 20 | Regulates alternative splicing of titin and other cardiac genes ( | ||
| Hormone signaling | Heart-specific serine proteinase | Serine protease which activates atrial natriuretic peptide ( | |
| Fibronectin type III domain-containing protein 5 | Is cleaved to become the secreted hormone irisin ( | ||
| Unknown | Double C2 gamma | Undetermined; possibly involved in calcium-dependent phospholipid binding activity ( | |
| Myosin binding protein H-like | Undetermined; possibly regulates cardiac function during hypoxia ( |
SR, sarcoplasmic reticulum.
Figure 2Genes within the pulmonary myocardium gene network are coregulated from loci on Chr1 and Chr2. (A) Heat-map analysis of eQTL for all 24 transcripts indicates regions of shared covariance on Chr1 and Chr2 (black arrowhead) with possible minor regions on Chr3, Chr4, Chr13, and Chr17 (white arrowhead). (B) Expression of Myh6 varied by 2.62-fold between BXD strains. Founder strains are shown in red and non-BXD strains are shown in blue. (C) Myh6 had a significant trans eQTL (LRS >17.5, red line) which mapped to Chr1: 33 ± 1 Mb. The genomic position of Myh6 is indicated by a ▴. (D) Expression of Tnni3 varied by 2.35-fold between BXD strains. (E) Tnni3 had a significant trans eQTL on Chr2 spanning 68.8 ± 0.4 Mb. (F) Tnni3 also had a second trans eQTL peak that was a suggestive eQTL (LRS >10.5, gray line) mapping to Chr2: 77.5 ± 1 Mb.
All transcripts except sarcolipin were regulated from an eQTL that mapped to Chr1 and/or Chr2
| Gene Name | Location | Range (-fold) | eQTL | |||
|---|---|---|---|---|---|---|
| Chromosome | Location | Genes | LRS | |||
| Chr7: 4.469 | 2.38 | Chr2 | 68.4–69.2 | 9 | >17.78 | |
| Chr2 | 76.4–80.1 | 20 | >11.02 | |||
| Chr3: 108.178 | 2.90 | Chr1 | 32.5–34.5 | 15 | >10.93 | |
| Chr2 | 77.8–78.7 | 6 | ||||
| Chr2 | 68.4–69.5 | 11 | ||||
| Chr4 | 49.6–54.9 | 27 | ||||
| Chr17 | 62.9–64 | 5 | ||||
| Chr11: 5.796 | 2.65 | Chr2 | 68.5–69.5 | 13 | >10.92 | |
| Chr17 | 62.9–64 | 5 | ||||
| Chr18 | 9.6–11 | 14 | ||||
| Chr1: 137.745 | 2.51 | Chr2 | 68.9–69.2 | 6 | >10.87 | |
| Chr13 | 116–116.35 | 1 | ||||
| Chr10: 53.065 | 4.15 | Chr2 | 65.5–68.9 | 19 | >10.77 | |
| Chr2 | 77.5–94 | 362 | ||||
| Chr2 | 113.4–113.7 | 8 | ||||
| Chr2 | 133.2–135.9 | 10 | ||||
| Chr14: 55.560 | 2.62 | Chr1 | 32.2–34 | 9 | >17.62 | |
| Chr1 | 23–25.1 | 17 | >10.88 | |||
| Chr4: 128.821 | 2.26 | Chr2 | 65.5–69.7 | 32 | >10.77 | |
| Chr2 | 79–80 | 7 | ||||
| Chr5: 122.903 | 2.03 | Chr1 | 32.2–34.5 | 15 | >10.89 | |
| Chr2 | 77.5–78.5 | 2 | ||||
| Chr4 | 29–32 | 7 | ||||
| Chr8: 87.848 | 2.95 | Chr1 | 32.5–34 | 9 | >10.77 | |
| Chr2 | 68.6–69.4 | 8 | ||||
| Chr13: 11.645 | 3.09 | Chr1 | 32.5–35 | 24 | >10.84 | |
| Chr4 | 31–32.5 | 4 | ||||
| Chr2: 55.450 | 5.40 | Chr2 | 65.7–70.8 | 32 | >16.51 | |
| Chr3 | 35.8–37 | 9 | >10.48 | |||
| Chr6 | 14–17 | 6 | ||||
| Chr2: 90.975 | 4.16 | Chr2 | 76.5–93.8 | 365 | >16.98 | |
| Chr2 | 65.5–70.5 | 36 | >10.6 | |||
| Chr14: 55.590 | 2.89 | Chr1 | 32–34.5 | 15 | >10.99 | |
| Chr6 | 67.5–76 | 103 | ||||
| Chr17 | 63–64 | 5 | ||||
| Chr9: 53.698 | 2.37 | Chr17 | 57–66 | 45 | >10.92 | |
| Chr19: 4.006 | 2.32 | Chr1 | 23–25.5 | 17 | >17.35 | |
| Chr2 | 68.6–70.3 | 20 | >10.82 | |||
| Chr6 | 13–15 | 11 | ||||
| Chr1: 137.747 | 2.33 | Chr1 | 32.2–34.5 | 15 | >10.89 | |
| Chr19: 53.941 | 2.60 | Chr2 | 76–94 | 365 | >10.84 | |
| Chr2 | 68.9–69.3 | 8 | ||||
| Chr4 | 49.5–54.9 | 32 | ||||
| Chr6 | 56.5 | 2 | ||||
| Chr10: 53.063 | 4.17 | Chr1 | 32.2–35 | 24 | >10.75 | |
| Chr2 | 77.5–78.5 | 2 | ||||
| Chr2 | 133.2–135.9 | 9 | ||||
| Chr10: 32.919 | 2.44 | Chr1 | 154.7–155.8 | 13 | >17.4 | |
| Chr1 | 145.4–146 | 9 | >10.7 | |||
| Chr1 | 160.17–160.29 | 2 | ||||
| Chr2 | 65.5–69.8 | 36 | ||||
| Chr3 | 28–36 | 60 | ||||
| Chr5: 72.691 | 3.61 | Chr1 | 32.5–35 | 24 | >10.73 | |
| Chr4 | 31.5–36 | 38 | ||||
| Chr11: 104.445 | 3.56 | Chr11 | 100.5–107 | 171 | >10.89 | |
| Chr1 | 32–34.5 | 13 | ||||
| Chr2 | 69–69.5 | 10 | ||||
| Chr2: 55.449 | 2.84 | Chr2 | 68.6–69.8 | 20 | >10.83 | |
| Chr2 | 88–92 | 135 | ||||
| Chr16: 28.189 | 2.56 | Chr1 | 32.5 –34.5 | 15 | >10.99 | |
| Chr6 | 22–24.5 | 18 | ||||
| Chr9: 24.525 | 3.17 | Chr1 | 32.5–34.5 | 15 | >10.94 | |
| Chr3 | 28–36.5 | 67 | ||||
Location (megabase) was defined as the genomic coordinates at which the eQTL peak crosses the suggested or significant LRS threshold.
Identification, function, and transcript expression of genes within an eQTL on Chr 1 and 2
| Linkage Peak | Gene | SNP Count | Function (GeneCards) | Fantom5 (TPM) |
|---|---|---|---|---|
| Chr1: 32 Mb | 630 | RNA-binding protein that plays a role in the regulation of alternative splicing | <1 | |
| 10 | Predicted gene | None | ||
| 16 | DNA primase, p58 subunit; an enzyme that plays a key role in the replication of DNA | 6 | ||
| 0 | Uncharacterized protein, no biological data | <1 | ||
| 1 | This gene encodes a small GTPase of the Ras superfamily; may play a role in central nervous system development by antagonizing SHH signaling | 4.06 | ||
| 2 | Competes with Hip for binding to the Hsc70/Hsp70 ATPase domain and promotes substrate release | 3.51 | ||
| 16 | Involved in transcriptional regulation; coactivator for steroid receptors | 9.79 | ||
| 31 | Among its related pathways are Notch signaling pathways | <1 | ||
| 340 | This gene encodes a member of the plakin protein family of adhesion junction plaque proteins | 20.14 | ||
| Chr2: 69 Mb | 117 | Uncharacterized protein, no biological data | None | |
| 33 | Related pathways are sphingolipid metabolism | 47.11 | ||
| 0 | Uncharacterized protein, no biological data | None | ||
| 10 | A potent mediator in biologic processes such as neurotransmission, inflammatory response, and vascular homeostasis | 106.79 | ||
| 2 | Involved in kinetochore–microtubule interaction and spindle checkpoint | None | ||
| 0 | Enzyme belonging to the glucose-6-phosphatase catalytic subunit family | None | ||
| 41 | Member of the superfamily of ATP-binding cassette (ABC) transporters | None | ||
| 54 | This protein demonstrates oxidoreductase activity and may additionally function as a transcriptional repressor in the nucleus | None | ||
| 199 | LRP2 protein is critical for the reuptake of numerous ligands, including lipoproteins, sterols, vitamin-binding proteins, and hormones | 36.58 | ||
| Chr2: 78 Mb | 7 | This gene encodes titin, a large abundant protein of striated muscle; titin also contains binding sites for muscle-associated proteins | 24.76 | |
| 2 | Role in radial migration and centrosomal function | 43.05 | ||
| 4 | Docking protein directing membrane turnover | <1 | ||
| 2 | Nucleic acid binding and p53 binding | <1 | ||
| 1 | Required for pre-mRNA splicing and for exon–junction complex assembly | <1 | ||
| 15 | Uncharacterized protein, no biological data | None |
TPM, tags per million.
ChIP-seq enrichment of Nkx2-5, Srf, and Mef2a in genomic regions proximal to genes within the pulmonary myocardium gene network and candidate upstream regulators
| Gene | Correlated with NKX2-5 ( | Dupay | |||||
|---|---|---|---|---|---|---|---|
| NKX2-5 | SRF | MEF2A | NKX2-5 | SRF | MEF2A | ||
| Yes, 0.613 | No | No | No | No | No | No | |
| Yes, 0.563 | Yes | No | Yes | Yes | Yes | No | |
| Yes, 0.454 | No | No | No | Yes | Yes | No | |
| Yes, 0.426 | No | Yes | Yes | Yes | Yes | Yes | |
| Yes, 0.539 | No | No | Yes | No | No | No | |
| Yes, 0.454 | No | Yes | Yes | No | No | No | |
| Yes, 0.427 | No | No | No | No | Yes | No | |
| No | Yes | Yes | Yes | Yes | Yes | Yes | |
| Yes, 0.501 | No | No | No | No | No | No | |
| Yes, 0.394 | No | No | No | Yes | Yes | No | |
| Yes, 0.397 | No | No | No | No | No | No | |
| Yes, 0.597 | Yes | No | Yes | No | Yes | No | |
| Yes, 0.421 | No | No | No | Yes | Yes | Yes | |
| Yes, 0.459 | No | No | No | No | No | No | |
| Yes, 0.631 | No | No | No | No | No | No | |
| Yes, 0.585 | No | No | No | Yes | Yes | No | |
| Yes, 0.466 | Yes | Yes | Yes | No | No | No | |
| No | No | No | No | Yes | Yes | Yes | |
| Yes, 0.510 | No | No | No | No | Yes | No | |
| Yes, 0.404 | No | No | No | Yes | Yes | No | |
| No | Yes | Yes | Yes | Yes | Yes | No | |
| No | No | No | No | Yes | No | No | |
| No | No | No | No | Yes | Yes | No | |
| No | No | No | No | Yes | Yes | No | |
| No | No | No | No | No | No | No | |
| No | No | Yes | Yes | No | Yes | Yes | |
Enriched GO terms and signaling pathways related to the coexpression of pulmonary myocardium-associated genes
| Category | Name | Genes | |
|---|---|---|---|
| Biological process | Muscle system process | 21 | 3.04 |
| Muscle contraction | 18 | 3.70 | |
| Blood circulation | 20 | 1.63 | |
| Circulatory system process | 20 | 1.63 | |
| Heart contraction | 15 | 9.39 | |
| Heart process | 15 | 9.39 | |
| System process | 31 | 9.18 | |
| Striated muscle contraction | 12 | 3.35 | |
| Cardiac muscle tissue development | 14 | 4.36 | |
| Striated muscle tissue development | 17 | 4.23 | |
| Molecular function | Cytoskeletal protein binding | 20 | 4.63 |
| Titin binding | 4 | 3.04 | |
| Protein binding | 47 | 7.20 | |
| Inorganic cation transmembrane transporter activity | 11 | 2.66 | |
| Cation transmembrane transporter activity | 11 | 0.0001 | |
| Monovalent inorganic cation transmembrane transporter activity | 8 | 0.0002 | |
| Metal ion transmembrane transporter activity | 9 | 0.0002 | |
| Actin binding | 9 | 0.0002 | |
| Transmembrane transporter activity | 13 | 0.0005 | |
| Ion channel binding | 4 | 0.0006 | |
| Cellular component | Sarcomere | 20 | 3.94 |
| Contractile fiber | 21 | 6.59 | |
| Contractile fiber part | 20 | 9.05 | |
| Myofibril | 20 | 2.56 | |
| I-band | 12 | 1.36 | |
| A-band | 8 | 6.44 | |
| Z-disc | 11 | 7.63 | |
| Sarcoplasmic reticulum | 9 | 1.12 | |
| Sarcoplasm | 9 | 3.02 | |
| M-band | 5 | 1.46 | |
| KEGG pathway | Dilated cardiomyopathy | 11 | 5.71 |
| Cardiac muscle contraction | 10 | 1.12 | |
| Hypertrophic cardiomyopathy | 10 | 1.12 | |
| Calcium signaling pathway | 7 | 1.90 | |
| Arrhythmogenic right ventricular cardiomyopathy | 4 | 1.06 | |
| Tight junction | 4 | 0.0001 | |
| Focal adhesion | 4 | 0.0003 | |
| Regulation of actin cytoskeleton | 4 | 0.0005 | |
| WikiPathway | Striated muscle contraction | 11 | 7.67 |
| Calcium regulation in the cardiac cell | 7 | 7.75 | |
| Heart development | 4 | 4.95 | |
| Myometrial relaxation and contraction pathways | 5 | 6.19 | |
| miR-1 in cardiac development | 2 | 1.12 | |
| MicroRNAs in cardiomyocyte hypertrophy | 4 | 1.94 | |
| G protein signaling pathways | 3 | 0.0005 |
Adjusted for multiple tests.
Figure 3Human phenotypes associated with the pulmonary myocardium coexpression gene network (PM-CGN) are associated with abnormal cardiac function. Phenotypes associated with the PM-CGN are related to muscle and cardiovascular system dysfunction. Pathways enriched with genes from the PM-CGN are shown in red.
The pulmonary myocardium gene coexpression network contains genes involved in ion transport that are associated with arrhythmia and dysregulated in atrial fibrillation
| Genes Involved in Ion Handling | |||||||
|---|---|---|---|---|---|---|---|
| Gene | Name | Function | Association with Arrhythmia | FDR < 0.05 | Fold-change | Cohort | |
| Ankyrin B (neuronal) | Required for targeting and stability of Na/Ca exchanger 1 in cardiomyocytes | Type 4 long-QT cardiac arrhythmia ( | No change | ||||
| Calcium channel, voltage-dependent, α-2/δ subunit 2 | This gene encodes the α-2/δ subunit of the voltage-dependent calcium channel complex. | No evidence | 3.5 | 1.338 | 0.58825 | AF/AF | |
| Sodium channel, voltage-gated, type V α subunit | This protein mediates the voltage-dependent sodium ion permeability of excitable membranes; responsible for the initial upstroke of the action potential in an electrocardiogram | Long QT syndrome type 3 and myotonic dystrophy ( | No change | ||||
| Ryanodine receptor 2 (cardiac) | Mediator of SR calcium storage and release | Atrial fibrillation ( | No change | ||||
| Voltage-gated potassium channel subunit Kv4.2 | This gene encodes a voltage-activated A-type potassium ion channel prominent in the repolarization phase of the action potential. | No evidence | No change | ||||
| Potassium inwardly rectifying channel, subfamily J, member 3 | Subunit of the muscarinic potassium channel (KCHa), important in regulation of heart rate | No evidence ( | No change | ||||
| Potassium inwardly rectifying channel, subfamily J, member 5 | The encoded protein may associate with two other G-protein-activated potassium channels to form a multimeric pore-forming complex. | Andersen–Tawil syndrome ( | 0.00112 | 0.0091709 | 0.71886 | AF/AF | |
| Cardiac muscle/slow twitch Ca++ transporting ATPase | Transports calcium from the cytosol to the SR lumen during muscle relaxation | No evidence | 4.5 | 1.242 | 1.62812 | AF/AF | |
| Triadin | Forms a complex with Ryr2 to coordinate release of calcium from the SR | Ventricular tachycardia, long QT syndrome ( | No change | ||||
| Myozenin 2 | The protein encoded by this gene binds to calcineurin, a phosphatase involved in calcium-dependent signal transduction in diverse cell types. | Hypertrophic cardiomyopathy with arrhythmia ( | 0.00014 | 0.0017485 | 0.73941 | AF/AF | |
| Calsequestrin 2 (cardiac muscle) | The protein is a calcium binding protein that stores calcium for muscle function. | Catecholaminergic polymorphic ventricular tachycardia ( | No change | ||||
| Cysteine and glycine-rich protein 3 (cardiac LIM protein) | Plays a crucial and specific role in the organization of cytosolic structures in cardiomyocytes and is essential for calcineurin anchorage to the Z-line. | Hypertrophic cardiomyopathy ( | 3.3 | 2.385 | 1.82455 | AF/AF | |
| Phospholamban | Negative regulator of SERCA2a | Ventricular arrhythmia ( | No change | ||||
| Sarcolipin | Negative regulator of SERCA2a | Atrial fibrillation ( | 0.00511 | 0.0303076 | 0.76185 | AF/AF | |
| Fibroblast growth factor 12 | Modulation of sodium and calcium channel function | Atrial fibrillation ( | No change | ||||
| Gap junction protein, α-3, 46 kDa (Connexin 46) | The protein encoded by this gene is a connexin and is a component of lens fiber gap junctions. | Heart failure and uncoordinated ventricular contraction in zebrafish ( | 0.00021 | 0.0056234 | 1.68501 | AF/AF | |
AF/AF, indicative of persistent atrial fibrillation; AF/SR, indicative of susceptibility to atrial fibrillation; SR, sarcoplasmic reticulum; NoAF, a cohort with no history of atrial fibrillation.
Figure 4TNNI3 and ACTA2 are localized to different structures in mouse lung. Serial sections of lung tissue were immunostained for (A) ACTA2, (B) TNNI3, (C) ACTC1, and (D) IgG isotype control (Isotype). Images in right-hand panels (bar, 60 μm) show detail from black boxes in left-hand panels (bar, 200 μm). Distinct cell-type localization of TNNI3 in striated muscle (white ←) and ACTA2 in smooth muscle (black ←) are indicated. Muscle striations are shown in (C) (*).
Figure 5A model for pulmonary myocardium gene regulation in response to hemodynamic stress. Based on our gene network analysis we propose that hemodynamic changes trigger mechanosensory (stretch-stress) signaling from the sarcomere via TTN, and initiate NO signaling cascades which are transmitted to the myocyte nucleus via NOSTRIN. These signals initiate dynamic regulation of gene expression to enable fine-tuning of the contractile properties of the pulmonary myocardium. Gene expression changes may also be regulated at the post-transcriptional level by RBM20 which could feedback to regulate Nostrin, Ttn, and Zfp451. Collectively, these effects are predicted to result in altered contractile properties, ion handling, and hormonal signaling in the pulmonary myocardium to direct an effective response to the initial hemodynamic cue.